Association between IVS3 +17T/C CD28 gene polymorphism and the acute kidney allograft rejection.

[1]  B. Charpentier.  Belatacept: a novel immunosuppressive agent for kidney transplant recipients , 2012, Expert review of clinical immunology.

[2]  A. Sharpe,et al.  Role of the PD‐1 Pathway in the Immune Response , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  K. Safranow,et al.  The impact of rs231775 (+49AG) CTLA4 gene polymorphism on transplanted kidney function. , 2012, Annals of transplantation.

[4]  M. Karimi,et al.  Association of genetic variation in co-stimulatory molecule genes with outcome of liver transplant in Iranian patients. , 2012, Gene.

[5]  M. H. Ensom,et al.  Belatacept: A New Biologic and Its Role in Kidney Transplantation , 2012, The Annals of pharmacotherapy.

[6]  F. Vincenti,et al.  Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. , 2011, Seminars in immunology.

[7]  Kristen E. Pauken,et al.  The role of the PD‐1 pathway in autoimmunity and peripheral tolerance , 2011, Annals of the New York Academy of Sciences.

[8]  M. Tokunaga,et al.  Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. , 2010, Immunity.

[9]  D. Janczak,et al.  The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. , 2010, Transplant immunology.

[10]  D. Mueller.  Mechanisms maintaining peripheral tolerance , 2010, Nature Immunology.

[11]  Y. Gorgi,et al.  Genetic polymorphisms of immunoregulatory proteins in acute renal allograft rejection. , 2009, Transplantation proceedings.

[12]  R. Friedline,et al.  CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance , 2009, The Journal of experimental medicine.

[13]  K. Salmela,et al.  Association of Genetic Variation in Inducible Costimulator Gene With Outcome of Kidney Transplantation , 2009, Transplantation.

[14]  M. Lefranc,et al.  The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. , 2009, Molecular immunology.

[15]  F. Cosio,et al.  Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  J. Madrenas,et al.  A molecular perspective of CTLA-4 function. , 2006, Annual review of immunology.

[17]  Mary Collins,et al.  The B7 family of immune-regulatory ligands , 2005, Genome Biology.

[18]  A. Sharpe,et al.  The B7/CD28 costimulatory family in autoimmunity , 2005, Immunological reviews.

[19]  S. Khoury,et al.  The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. , 2004, Immunity.

[20]  Jeffrey A. Bluestone,et al.  When ligand becomes receptor—tolerance via B7 signaling on DCs , 2002, Nature Immunology.

[21]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[22]  M. Sayegh,et al.  The role of novel T cell costimulatory pathways in autoimmunity and transplantation. , 2002, Journal of the American Society of Nephrology : JASN.

[23]  Mary Collins,et al.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. , 2002, Annual review of immunology.

[24]  G. Zhu,et al.  Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS , 2000 .

[25]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[26]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.